Last reviewed · How we verify
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
The purpose of this study is to find out what effects a new drug, buparlisib, has on chronic lymphocytic leukemia.
Details
| Lead sponsor | Canadian Cancer Trials Group |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 14 |
| Start date | Mon Apr 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Chronic Lymphocytic Leukemia
Interventions
- Buparlisib
Countries
Canada